Research output per year
Research output per year
Personal profile
Research interests
My research program focuses on:
1. Gene down regulation strategies (RNAi and antisense oligonucleotides) to understand disease pathogenesis and provide novel therapies for neurodegenerative diseases, in particular amyotrophic lateral sclerosis (ALS)
2. How dysfunction of mitochondria causes loss of motor neurons.
Clinical interests
ALS and neurological disorders
Fingerprint
Dive into the research topics where Timothy Miller is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Adaptive Platform Trials to Transform Amyotrophic Lateral Sclerosis Therapy Development
for the Healey ALS Platform Trial Study Group, HEALEY ALS Platform Trial Study Group, Biostatisticians, Investigators, Clinical Operations Team & Medical Monitors, Feb 2022, In: Annals of neurology. 91, 2, p. 165-175 11 p.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
Antisense Oligonucleotides for the Study and Treatment of ALS
Boros, B. D., Schoch, K. M., Kreple, C. J. & Miller, T., 2022, (Accepted/In press) In: Neurotherapeutics.Research output: Contribution to journal › Review article › peer-review
-
Astrocytic 4R tau expression drives astrocyte reactivity and dysfunction
Ezerskiy, L. A., Schoch, K. M., Sato, C., Beltcheva, M., Horie, K., Rigo, F., Martynowicz, R., Karch, C. M., Bateman, R. J. & Miller, T. M., Jan 11 2022, In: JCI Insight. 7, 1, 152012.Research output: Contribution to journal › Article › peer-review
Open Access -
Disentangling glial diversity in peripheral nerves at single-nuclei resolution
Yim, A. K. Y., Wang, P. L., Bermingham, J., Hackett, A., Strickland, A., Miller, T., Ly, C., Mitra, R. D. & Milbrandt, J., Feb 2022, In: Nature neuroscience. 25, 2, p. 238-251 14 p.Research output: Contribution to journal › Article › peer-review
1 Scopus citations -
Prescription and acceptance of durable medical equipment in FORTITUDE-ALS, a study of reldesemtiv in ALS: post hoc analyses of a randomized, double-blind, placebo-controlled clinical trial
ON BEHALF OF THE FORTITUDE-ALS STUDY GROUP, 2022, In: Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 23, 3-4, p. 263-270 8 p.Research output: Contribution to journal › Article › peer-review
Open Access